Compare multi-agent consensus ratings, forecast paths, AI price targets, expected return, fundamentals, analyst disagreement, risks, and the investment thesis across short- and long-term horizons.

JNJ.NYSE

Johnson & Johnson

Healthcare | Drug Manufacturers - General

Healthcare conglomerate specializing in pharmaceuticals, medical devices, and consumer health products with trusted global brands.

Flagship Insight

Why This Sovereign-Grade Healthcare Giant Faces a Silent Valuation Gravity Well

A sharp divergence exists between the market's safe-haven narrative and the mathematical reality of multiple contraction. While high consensus supports the asset's fortress balance sheet and robust free cash flow, the primary driver of predatory capital allocation is offset by regulatory pricing risks and patent cliff erosion.

Forecast TimelineUpdated On Jul 02 2026

Johnson & Johnson (JNJ) Stock Forecast and AI Rating

Recommendation

Hold & Monitor

Model signals are balanced; wait for clearer evidence.

2027

1-Year

NEUTRAL

$272

+3.2%

+8.6% IF INCL. DIVS

2029

3-Year

N/A

$306

+22%

2031

5-Year

NEUTRAL

$344

+31%

+53% IF INCL. DIVS

LATEST DEEP FORECAST ANALYSIS BY iPULSE AI ENGINE | Jul 05, 2026

Visionary, Superintelligence, Insider, Strategist, Value Seeker, Vulture, Whistleblower, and more.

Elon Musk (Visionary), Superintelligence (Anthropologist), Machiavelli (Insider), Ray Dalio (Strategist), Warren Buffett (Value Purist), Michael Burry (Vulture), Sherlock Holmes (Whistleblower).

Research support only. We don't give financial advice.

Computed on these frontier AI models

Gemini

Claude

ChatGPT

Grok

Investment Thesis Takeaway

Expert LanguageExpert Quant Language

Explained Simply

Interactive forecast chart

Expert Language

Explained Simply

The asset presents a classic dichotomy between operational excellence and valuation gravity. While the core business generates robust, inelastic free cash flows backed by a AAA-rated balance sheet, a starting valuation multiple near thirty times trailing earnings creates a structural headwind. Over a five-year horizon, the base-case narrative projects steady fundamental compounding driven by MedTech integration, post-spinoff margin expansion, and predatory capital allocation targeting distressed biotech assets. However, this intrinsic compounding will likely be offset by multiple contraction as the market adjusts to a higher-for-longer interest rate regime and regulatory pricing constraints.

Key insights

Pristine AAA-rated balance sheet provides a permanent cost-of-capital advantage and unconstrained optionality for counter-cyclical M&A.
Post-spinoff operational purity drives gross margins to seventy-three percent, insulating earnings from inflationary shocks.
The impending Stelara patent cliff acts as a telegraphed headwind, requiring flawless pipeline execution to offset revenue decay.
Restrictive monetary policy and elevated risk-free yields exert persistent downward pressure on premium valuation multiples.
Bipartisan drug pricing initiatives and international reference pricing frameworks place a structural ceiling on domestic net realized prices.
Shareholder returns will be heavily supported by a reliable dividend yield and disciplined, opportunistic share repurchases.
Disagreements persist regarding the speed of pipeline replacement and the ultimate financial impact of legacy mass-tort litigation.

Preparing your access...

AI Consensus

AI Opinions

Company Profile

Johnson & Johnson quarterly forecast scenarios

One row per forecast quarter. Asset scenario targets are shown in USD; benchmark values are shown in USD.

Quarterly Bear Case, Base Case, Bull Case, and S&P 500 benchmark forecasts for Johnson & Johnson.
Quarter	Forecast date	Bear Case (USD)	Base Case (USD)	Bull Case (USD)	S&P 500 benchmark (USD)
Quarter 1+3M	Oct 02, 2026	$252.52	$263.48	$273.56	$736.09
Quarter 2+6M	Jan 02, 2027	$244.94	$264.30	$281.77	$724.14
Quarter 3+9M	Apr 02, 2027	$240.04	$264.38	$287.40	$713.57
Quarter 4+1Y	Jul 02, 2027	$235.24	$266.52	$298.90	$723.38
Quarter 5+15M	Oct 02, 2027	$237.50	$271.58	$304.88	$716.61
Quarter 6+18M	Jan 02, 2028	$232.84	$275.06	$314.02	$738.34
Quarter 7+21M	Apr 02, 2028	$230.52	$277.69	$320.27	$746.91
Quarter 8+2Y	Jul 02, 2028	$230.52	$282.06	$336.29	$771.93
Quarter 9+27M	Oct 02, 2028	$235.13	$288.86	$343.01	$782.73
Quarter 10+30M	Jan 02, 2029	$227.89	$294.68	$349.87	$807.31
Quarter 11+33M	Apr 02, 2029	$225.61	$298.37	$360.37	$822.72
Quarter 12+3Y	Jul 02, 2029	$230.12	$303.04	$367.58	$846.10
Quarter 13+39M	Oct 02, 2029	$230.12	$305.70	$374.93	$852.53
Quarter 14+42M	Jan 02, 2030	$232.42	$313.29	$382.43	$882.91
Quarter 15+45M	Apr 02, 2030	$227.77	$317.84	$382.43	$900.46
Quarter 16+4Y	Jul 02, 2030	$230.05	$321.56	$386.25	$922.67
Quarter 17+51M	Oct 02, 2030	$227.75	$324.01	$393.98	$935.91
Quarter 18+54M	Jan 02, 2031	$223.19	$330.74	$401.86	$952.30
Quarter 19+57M	Apr 02, 2031	$225.43	$337.51	$409.89	$976.28
Quarter 20+5Y	Jul 02, 2031	$225.43	$344.28	$418.09	$1,002

Alpha Gap and Advisor Disagreement

Alpha Gap

The core information gap lies in the decoupling of business quality from investment quality. While the crowd correctly identifies the asset as an impenetrable commercial fortress, it misprices the security by conflating business safety with investment safety. Paying a premium multiple for a mature enterprise facing patent cliffs in a high-rate environment leaves zero margin of safety, transforming a phenomenal business into a mediocre entry point. Furthermore, the market overlooks the predatory advantage of holding a AAA-equivalent balance sheet in a capital-scarce regime. While high rates suffocate subscale biotech funding, the asset can acquire distressed innovation at generational lows. The variant perception is that the asset is not a passive bond proxy, but a highly concentrated, pure-play biopharma and advanced medical technology apex predator capable of offensive capital allocation.

Advisor Disagreement

The primary disagreement across the reports centers on the starting valuation multiple and the timing of multiple compression. Some perspectives argue that the current premium multiple is a temporary safe-haven anomaly that will contract rapidly as risk-free yields remain elevated. Others contend that the premium is justified by the company's structural margin expansion post-spinoff and its predatory capital allocation advantages. Additionally, there is divergence regarding the speed at which the new immunology and oncology pipeline can offset the Stelara patent cliff, with estimates of revenue stabilization ranging from twelve months to three years.

Financial Reviews by iPulse AI

Earnings and financials

The company's financial engine remains incredibly strong, but it is currently facing a period of transition. On the positive side, the business generates a massive and stable flow of cash, bringing in nearly twenty billion dollars in free cash flow annually, with overall revenues growing at a healthy six percent. However, the company's net income has shown some short-term volatility due to one-time legal settlements and the loss of patent protection on its major drug, Stelara. Most assessments agree that the underlying cash generation is bulletproof and highly valuable in today's uncertain economy. The main area of disagreement is whether the company's slow-and-steady growth can justify its currently high stock price. While some believe the steady cash flow makes it a safe bet, others warn that investors are paying too much of a premium, which could limit future stock gains.

Profitability and margins

The company boasts elite profitability, with gross margins stabilizing at an impressive seventy-three percent and operating margins hovering around twenty-seven percent. This incredible profitability is a direct result of selling off its lower-margin consumer health division, leaving a highly focused and efficient business. There is strong consensus that these high margins provide an excellent buffer against inflation and rising supply chain costs. However, there is a clear clash of opinions regarding the future path of these margins. Some analysts believe that upcoming government rules to cap drug prices and the rising costs of manufacturing products domestically will put a ceiling on profits, causing margins to shrink slightly. Others argue that the company's transition into high-margin robotic medical devices and advanced cancer therapies will offset these pressures, allowing profitability to remain at historic highs.

Balance sheet and leverage

The company's balance sheet is widely recognized as an absolute financial fortress, boasting one of the very few remaining AAA credit ratings in the corporate world. With a very conservative debt level and massive interest coverage, the company is completely insulated from the pressure of high interest rates. There is high consensus that this financial strength provides incredible safety during economic downturns. Furthermore, it gives the company a unique offensive advantage: while smaller, cash-strapped competitors struggle to survive, this giant can use its massive cash reserves to buy up promising new drug technologies at bargain prices. The only notable concern or point of caution is the massive, off-balance-sheet risk of tens of thousands of ongoing lawsuits. While the company's financial safety net is strong enough to absorb these legal costs, a failure to settle these cases could eventually drain cash that would otherwise go to stock buybacks.

Capex and investment intensity

The company operates a highly efficient business model that does not require heavy spending on physical factories or equipment, which typically consumes only about five percent of its revenue. Instead, the real heavy lifting is done through its massive research and development budget, which stands at nearly fifteen billion dollars annually. This heavy spending is absolutely necessary to discover new treatments and protect the company's business from losing patents on older drugs. There is strong consensus that this self-funded investment strategy is a major advantage because the company does not need to borrow expensive money to grow. However, opinions differ on the efficiency of this spending. Some believe the company's shift toward advanced digital and artificial intelligence tools will make drug discovery faster and cheaper, while others worry the company is overpaying for outside acquisitions to plug its revenue holes.